Skip to main content

Secondary analysis of the FIELD randomized trial evaluated the performance of GFR slope in a non-glomerular model of estimated GFR decline

In brief

Fenofibrate increased kidney-event hazard 48% despite improving chronic eGFR slope

Among 9,795 adults followed for five years, fenofibrate caused an acute eGFR drop of about 9 mL/min/1.73 m2, improved chronic eGFR decline by 0.61 mL/min/1.73 m2 per year, yet increased the hazard of the composite kidney endpoint by 48%. Washout analyses reversed the total-slope finding, highlighting how an early eGFR drop can shape estimates of kidney effects.

Journal
Kidney international (Q1)
Published
19 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Alexandra Gallagher, Rachel L O'Connell, George Mangos, Brendan Smyth, Timothy M E Davis, Alicia J Jenkins, et al.
PMID
43057619
DOI
10.1016/j.kint.2026.10.034

Why clinicians should know about it

  • Picked for Nephrology (top studies of the week, 22 November 2026): Randomized-trial analysis informs CKD progression endpoints and fenofibrate effects

Abstract

INTRODUCTION: Glomerular Filtration Rate (GFR) decline is a recent surrogate kidney endpoint for trials. Estimated GFR (eGFR) decline has been modelled using GFR slope, correlating total and chronic GFR slopes with composite kidney endpoints. Several included interventions caused an initial eGFR decline mediated by glomerular hemodynamics. We tested the association of GFR slopes with clinical endpoints for fenofibrate, an agent with an acute, non-glomerular eGFR decline (i.e. no effect on inulin clearance). METHODS: The FIELD trial randomized adults to fenofibrate or placebo. Total slope was calculated using a repeated measures 2-slope linear mixed model for the entire intervention period. A three-year sensitivity analysis was performed. Chronic slope was calculated from month four. The composite kidney endpoint was doubling of serum creatinine or 40% decline/eGFR under 15 ml/min/1.73 m2/kidney death/kidney replacement therapy. The total slope from baseline to eight-week washout eGFR was an exploratory subgroup analysis. RESULTS: 9795 participants were followed for five years. Post-washout eGFR was ascertained in 660 sub-study participants. Fenofibrate produced an acute eGFR decline of -9.05 ml/min/1.73 m2. Fenofibrate improved chronic slope (significant between-group difference 0.61 ml/min/1.73 m2/ annum [95% CI 0.50 to 0.71]) but worsened total slope (significant between group difference -1.54, 95% CI -1.65 to -1.44). Fenofibrate significantly increased the clinical endpoint (hazard ratio 1.48, 95% CI 1.16 to 1.89). Washout analyses demonstrated treatment benefit on total slope, contrary to on-study analyses in the overall cohort. CONCLUSIONS: Conventional composite endpoints include surrogate components that may not always accord with measured kidney function, though widely accepted in trials. Total slope and the conventional composite yielded concordant treatment effects under an acute eGFR change both larger and mechanistically distinct from those in previous validation work, supporting the conclusion that total slope will produce similar results to conventional endpoints.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.